Abraham Ceesay Biography and Net Worth

Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor’s degree from Ithaca College and Master of Business Administration from Suffolk University’s Sawyer School of Management.

What is Abraham Ceesay's net worth?: The estimated net worth of Abraham Ceesay is at least $14.23 million as of September 23rd, 2026. Ceesay owns 456,767 shares of Rapport Therapeutics stock worth more than $14,228,292 as of October 7th. This net worth approximation does not reflect any other assets that Ceesay may own. Learn More about Abraham Ceesay's net worth.
How do I contact Abraham Ceesay?: The corporate mailing address for Ceesay and other Rapport Therapeutics executives is 99 High Street, Suite 2100, Boston, MA, 02110. Rapport Therapeutics can also be reached via phone at (857) 321-8020 and via email at [email protected]. Learn More on Abraham Ceesay's contact information.
Has Abraham Ceesay been buying or selling shares of Rapport Therapeutics?: Abraham Ceesay has not been actively trading shares of Rapport Therapeutics during the past quarter. Most recently, Abraham Ceesay sold 2,210 shares of the business's stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $39.17, for a transaction totalling $86,565.70. Following the completion of the sale, the chief executive officer now directly owns 456,767 shares of the company's stock, valued at $17,891,563.39. Learn More on Abraham Ceesay's trading history.
Who are Rapport Therapeutics' active insiders?: Rapport Therapeutics' insider roster includes David Bredt (Insider), Abraham Ceesay (CEO), Cheryl Gault (COO), James Healy (Director), Troy Ignelzi (CFO), Krishnaswamy Yeleswaram (Insider), and Wendy Young (Director). Learn More on Rapport Therapeutics' active insiders.
Are insiders buying or selling shares of Rapport Therapeutics?: During the last year, insiders at the sold shares 36 times. They sold a total of 1,097,113 shares worth more than $43,175,995.81. The most recent insider tranaction occured on September, 30th when COO Cheryl Gault sold 10,000 shares worth more than $331,900.00. Insiders at Rapport Therapeutics own 12.5% of the company. Learn More about insider trades at Rapport Therapeutics.
Information on this page was last updated on 9/30/2026.

Abraham Ceesay Insider Trading History at Rapport Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/23/2026	Sell	2,210	$39.17	$86,565.70	456,767
9/8/2026	Sell	8,210	$45.61	$374,458.10	458,977
8/25/2026	Sell	18,921	$49.57	$937,913.97	467,187
8/11/2026	Sell	28,958	$48.01	$1,390,273.58	486,108
8/10/2026	Sell	22,541	$46.26	$1,042,746.66	515,066
7/27/2026	Sell	2,210	$42.11	$93,063.10	537,607
2/18/2026	Sell	5,833	$29.34	$171,140.22	556,247
2/18/2026	Sell	5,083	$29.36	$149,236.88	20,729
1/20/2026	Sell	5,833	$26.12	$152,357.96	562,080
1/20/2026	Sell	5,083	$26.11	$132,717.13	25,812
12/17/2025	Sell	5,833	$29.64	$172,890.12	567,913
12/17/2025	Sell	5,083	$29.63	$150,609.29	30,895
11/17/2025	Sell	5,833	$25.19	$146,933.27	573,746
11/17/2025	Sell	5,083	$25.20	$128,091.60	35,978
10/15/2025	Sell	5,833	$25.81	$150,549.73	579,579
10/15/2025	Sell	5,083	$25.81	$131,192.23	41,061
9/17/2025	Sell	40,835	$26.32	$1,074,777.20	585,412
9/17/2025	Sell	35,585	$26.32	$936,597.20	46,144

Abraham Ceesay Buying and Selling Activity at Rapport Therapeutics

Rapport Therapeutics Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Today's Range

Now: $31.15

$30.01

$34.00

50 Day Range

MA: $43.19

$31.15

$52.50

2 Week Range

Now: $31.15

$23.75

$52.93

Volume

235,641 shs

Average Volume

502,692 shs

Market Capitalization

$1.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22